Delivery Order SPE2DB24D2205-SPE2DB25FECFG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $34,068.09 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count supply). This competitive, non-set-aside delivery order represents a firm fixed price contract with a completion date of June 3, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Valsartan-HCTZ is a combination antihypertensive medication used to manage high...
- The Defense Logistics Agency awarded a $7,300.63 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Valsartan-HCTZ 160-12.5 mg tablets (90-count) on June 2, 2025, with completion scheduled for June 3, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,542.97 to AmerisourceBergen Drug Corp for Valsartan-HCTZ 320-25 mg tablets (90-count supply). This competitively awarded, firm fixed-price delivery order was issued on August 15, 2025, with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. As a child delivery order under a...
- The Defense Logistics Agency awarded a $1,224.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Valsartan-HCTZ 160-12.5 mg tablets (90-count supply) on July 22, 2025, with completion scheduled for July 23, 2025. The contract represents a non-competitive, non-set-aside delivery order executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets in a quantity of 90 units, with a ceiling value of $1,697.07. This competitively awarded, firm fixed-price contract is classified as non-set-aside and was completed on August 5, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the delivery order from its location in...
- The Defense Logistics Agency awarded a $53,133 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90-count bottles of Valsartan-HCTZ 320-25 mg tablets, with completion scheduled for September 26, 2025. This competitive award, issued on September 25, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999 through December 2026. The pharmaceutical will be supplied...
- The Defense Logistics Agency awarded a delivery order valued at $23,124.56 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count units) under a firm fixed-price contract. This non-set-aside delivery order, awarded on September 18, 2025, with an ultimate completion date of September 19, 2025, represents a routine pharmaceutical procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in...
- This delivery order, awarded August 27, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides 90-count tablets of Valsartan-HCTZ 160-25 mg with a ceiling value of $3,617.52. The award is a firm fixed price, non-competitive set-aside delivery order executed under AmerisourceBergen's $999.99 billion indefinite delivery contract (SPE2DX) with DLA Troop Support Medical, which extends through December 2026. This parent contract serves as a comprehensive global...
- The Defense Logistics Agency awarded a $3,819.87 delivery order to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $77,079.86 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Valsartan-HCTZ 320-12.5 mg tablets in quantities of 90 units. This firm fixed-price delivery order, which was not set-aside and competed openly, is scheduled for completion by September 12, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FECFGDelivery Order
The Defense Logistics Agency awarded a $20,047.15 delivery order to AmerisourceBergen Drug Corp for 90-count tablets of Valsartan-HCTZ 320-25 mg, a combination antihypertensive medication used to treat high blood pressure. This competitively awarded, firm fixed-price delivery order was issued on May 12, 2025, with an ultimate completion date of May 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement through the federal medical supply chain supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of medications and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare programs globally. The company's extensive federal contract portfolio and competitive award history demonstrate its capability to fulfill diverse medical procurement requirements for the Department of Defense medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.0k | 5/12/25 |